Eosinophilic pneumonia caused by cefepime: A case report and review
Bruce M. Jones,
E. Yancey Murray,
Courtney Crosby,
Scott Rojas,
Christopher M. Bland
Affiliations
Bruce M. Jones
St. Joseph’s/Candler Health System, Inc., 5353 Reynolds Street, Savannah, GA, 31405, USA; University of Georgia College of Pharmacy, 5356 Reynolds Street, Savannah, GA, 31405, USA; Corresponding author at: St. Joseph's/Candler Health System, Inc., 5353 Reynolds Street, Savannah, GA, 31405, USA.
E. Yancey Murray
University of Georgia College of Pharmacy, 5356 Reynolds Street, Savannah, GA, 31405, USA
Courtney Crosby
University of Georgia College of Pharmacy, 5356 Reynolds Street, Savannah, GA, 31405, USA
Scott Rojas
St. Joseph’s/Candler Health System, Inc., 5353 Reynolds Street, Savannah, GA, 31405, USA; SouthCoast Health Savannah, 1326 Eisenhower Drive, Bldg 2, Savannah, GA, 31406, USA
Christopher M. Bland
St. Joseph’s/Candler Health System, Inc., 5353 Reynolds Street, Savannah, GA, 31405, USA; University of Georgia College of Pharmacy, 5356 Reynolds Street, Savannah, GA, 31405, USA
Eosinophilic pneumonia (EP) is characterized by accumulation of eosinophils in the lungs and has been associated with several medications, including antimicrobials. Cefepime is a commonly used broad-spectrum antimicrobial agent for the treatment of nosocomial infections but to date has not been associated with EP. We report the first documented case of EP secondary to cefepime for the treatment of pneumonia. The patient’s peripheral eosinophilia and leukocytosis resolved promptly after discontinuation of cefepime and initiation of steroid treatment.
